| Literature DB >> 34386008 |
Liudan Tu1, Churong Lin2, Ya Xie1, Xiaohong Wang2, Qiujing Wei1, Yanli Zhang1, Jieruo Gu1.
Abstract
Objective: Evaluate the MRI evidence of active inflammatory and chronic structural damages in radiographic axial spondyloarthritis (r-axSpA) and non-radiographic axial spondyloarthritis (nr-axSpA).Entities:
Keywords: MRI; ankylosing spondylitis; axial spondyloarthritis; inflammation; structural damage
Mesh:
Year: 2021 PMID: 34386008 PMCID: PMC8353186 DOI: 10.3389/fimmu.2021.700260
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1MRI findings of inflammatory and structural damage of SpA. (A) Bone marrow edema (BME) at the left side of sacroiliac joints (white arrows) in Coronal oblique STIR sequence. (B) Erosion of the right iliac bone on T1 weighted spin echo MRI (white arrows). (C) Fat metaplasia at the bilateral sacroiliac joints on T1 weighted spin echo MRI (white stars). (D) Backfill of the right iliac bone on T1 weighted spin echo MRI (white arrows). (E) Ankylosis of the bilateral sacroiliac joints on T1 weighted spin echo MRI (white stars).
Demographic features of included patients.
| Characteristics | All patients (n=254) | AS (n=202) | nr-axSpA (n=51) | |
|---|---|---|---|---|
| Age (years) | 31.74±9.14 | 31.7±9.25 | 31.88±8.77 | 0.9 |
| Male patients, n (%) | 201 (79.45) | 164 (81.19) | 37 (72.55) | 0.18 |
| Disease duration (years) | 7.91±6.56 | 8.68±6.50 | 4.94±5.95 | 0.0002 |
| HLA-B27, n (%) | 221 (87.35%) | 182 (90.1) | 39 (76.47) | 0.02 |
| Family history, n (%) | 60 (23.72) | 51 (25.25) | 9 (17.65) | 0.35 |
| CRP (mg/dl) | 18.66±23.99 | 20.05±25.18 | 13.19±17.75 | 0.06 |
| ESR (mm/H) | 26.07±24.13 | 26.54±23.22 | 24.18±27.58 | 0.53 |
| BASDAI (0-10) | 4.31±2.25 | 4.53±2.26 | 3.43±2.02 | 0.002 |
| BASFI (0-10) | 2.19±2.27 | 2.38±2.29 | 1.44±0.05 | 0.009 |
| ASDAS-CRP | 2.98±1.17 | 3.14±1.13 | 2.37±1.13 | <0.000 |
| Use of TNFi, n (%) | 84 (33.2%) | 63 (31.2%) | 21 (41.2%) | 0.19 |
Data were presented as mean±SD unless specifically indicated. HLA-B27, Human leukocyte antigen-B27; CRP, C-Reactive Protein; ESR, Erythrocyte Sedimentation Rate; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; TNFi, Tumor necrosis factor inhibitor.
MRI inflammatory and structural damages.
| Characteristics | All patients (n=253) | AS (n=202) | nr-axSpA (n=51) | BME≥2 (N=136) | BME<2 (N=117) |
|---|---|---|---|---|---|
| SPARCC (0-72) | 7.33 ± 12.02 | 8.08 ± 12.27* | 4.37 ± 10.55 | – | – |
| Fat metaplasia (0-40) | 7.95 ± 8.74 | 8.93 ± 9.15* | 4.06 ± 5.33 | 7.56 ± 9.34 | 8.41 ± 7.98 |
| Erosion (0-40) | 5.01 ± 6.41 | 5.13 ± 6.79 | 4.51 ± 4.60 | 3.36 ± 5.39η | 6.93 ± 6.97 |
| Backfill (0-20) | 1.51 ± 3.33 | 1.71 ± 3.35* | 0.75 ± 3.19 | 0.68 ± 2.19η | 2.48 ± 4.11 |
| Ankylosis (0-20) | 3.59 ± 6.72 | 4.49 ± 7.25* | 0.04 ± 0.28 | 5.37 ± 7.98η | 1.65 ± 4.10 |
SPARCC, the Spondyloarthritis Research Consortium of Canada; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial spondyloarthritis; BME, bone marrow edema. *Significant difference was found between AS and nr-axSpA patients.ηSignificant difference was found between patients with and without BME.
Factors associated with structural damages on MRI.
| Fat metaplasia | Erosion | Backfill | Ankylosis | |||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | |
| Spearmen’s rho, P value | β (95% CI) | Spearmen’s rho, P value | β (95% CI) | Spearmen’s rho, P value | β (95% CI) | Spearmen’s rho, P value | β (95% CI) | |
| Age |
| NA | -0.08, NS | NA | -0.07, NS | NA | -0.02, NS |
|
| Sex | -0.02, NS | NA | 0.10, NS | NA | -0.007, NS | NA |
|
|
| HLA-B27 | 0.11, NS | 3.09 (-0.13, 6.30) | -0.02, NS | NA | 0.09, NS | NA |
|
|
| Disease duration |
| NA |
| NA | -0.02, NS | NA |
|
|
| BASDAI |
|
|
|
| -0.10, NS | NA | 0.12, NS | NA |
| CRP | 0.04, NS | NA |
| NA | -0.02, NS | NA |
|
|
| ESR | -0.05, NS | NA | -0.06, NS | NA | 0.006, NS | NA | 0.12, NS | NA |
| ASDAS | -0.07, NS | NA |
| NA | -0.07, NS | NA |
| NA |
| SPARCC | 0.09, NS | NA |
|
|
|
|
|
|
HLA-B27, Human leukocyte antigen-B27; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-Reactive Protein; ESR, Erythrocyte Sedimentation Rate; ASDAS, Ankylosing Spondylitis Disease Activity Score; SPARCC, the Spondyloarthritis Research Consortium of Canada; NS, not significant; NA, not available.
Bold values means significant difference.